Dysregulation of the Pdx1/Ovol2/Zeb2 axis in dedifferentiated β-cells triggers the induction of genes associated with epithelial-mesenchymal transition in diabetes.
Animals
Cells, Cultured
Diabetes Mellitus, Type 2
/ genetics
Down-Regulation
Epithelial-Mesenchymal Transition
/ genetics
Female
HEK293 Cells
Homeodomain Proteins
/ genetics
Humans
Insulin-Secreting Cells
/ metabolism
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Sequence Analysis, RNA
Trans-Activators
/ genetics
Transcription Factors
/ genetics
Zinc Finger E-box Binding Homeobox 2
/ genetics
Dedifferentiation
Diabetes
Epithelial-to-mesenchymal transition
Insulin
Pancreatic β-cells
microRNA
Journal
Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
18
03
2021
revised:
24
04
2021
accepted:
04
05
2021
pubmed:
15
5
2021
medline:
25
3
2022
entrez:
14
5
2021
Statut:
ppublish
Résumé
β-cell dedifferentiation has been revealed as a pathological mechanism underlying pancreatic dysfunction in diabetes. We previously showed that increased miR-7 levels trigger β-cell dedifferentiation and diabetes. We used β-cell-specific miR-7 overexpressing mice (Tg7) to test the hypothesis that loss of β-cell identity triggered by miR-7 overexpression alters islet gene expression and islet microenvironment in diabetes. We performed bulk and single-cell RNA sequencing (RNA-seq) in islets obtained from β-cell-specific miR-7 overexpressing mice (Tg7). We carried out loss- and gain-of-function experiments in MIN6 and EndoC-bH1 cell lines. We analysed previously published mouse and human T2D data sets. Bulk RNA-seq revealed that β-cell dedifferentiation is associated with the induction of genes associated with epithelial-to-mesenchymal transition (EMT) in prediabetic (2-week-old) and diabetic (12-week-old) Tg7 mice. Single-cell RNA-seq (scRNA-seq) indicated that this EMT signature is enriched specifically in β-cells. These molecular changes are associated with a weakening of β-cell: β-cell contacts, increased extracellular matrix (ECM) deposition, and TGFβ-dependent islet fibrosis. We found that the mesenchymal reprogramming of β-cells is explained in part by the downregulation of Pdx1 and its inability to regulate a myriad of epithelial-specific genes expressed in β-cells. Notable among genes transactivated by Pdx1 is Ovol2, which encodes a transcriptional repressor of the EMT transcription factor Zeb2. Following compromised β-cell identity, the reduction in Pdx1 gene expression causes a decrease in Ovol2 protein, triggering mesenchymal reprogramming of β-cells through the induction of Zeb2. We provided evidence that EMT signalling associated with the upregulation of Zeb2 expression is a molecular feature of islets in T2D subjects. Our study indicates that miR-7-mediated β-cell dedifferentiation induces EMT signalling and a chronic response to tissue injury, which alters the islet microenvironment and predisposes to fibrosis. This research suggests that regulators of EMT signalling may represent novel therapeutic targets for treating β-cell dysfunction and fibrosis in T2D.
Identifiants
pubmed: 33989778
pii: S2212-8778(21)00093-4
doi: 10.1016/j.molmet.2021.101248
pmc: PMC8184664
pii:
doi:
Substances chimiques
Homeodomain Proteins
0
MOVO protein, mouse
0
Ovol2 protein, human
0
Trans-Activators
0
Transcription Factors
0
ZEB2 protein, human
0
ZEB2 protein, mouse
0
Zinc Finger E-box Binding Homeobox 2
0
pancreatic and duodenal homeobox 1 protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101248Subventions
Organisme : Wellcome Trust
ID : WT098424AIA
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S025618/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N00275X/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L020149/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R022259/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212625/Z/18/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010676/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J0003042/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L02036X/1
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier GmbH.. All rights reserved.